Eline van der Burg

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

Sven Rottenberg, Janneke E. Jaspers, Ariena Kersbergen et al. · Proceedings of the National Academy of Sciences · 2008 · 943 citations · Full text

Breast Oncology, Pathology, Cancer Biology +17

Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin

Bastiaan Evers, Rinske Drost, Eva Schut et al. · Clinical Cancer Research · 2008 · 331 citations · Full text

Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer

Petra ter Brugge, Petra Kristel, Eline van der Burg et al. · JNCI Journal of the National Cancer Institute · 2016 · 201 citations

BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1

Rinske Drost, Kiranjit K. Dhillon, Hanneke van der Gulden et al. · Journal of Clinical Investigation · 2016 · 137 citations · Full text

Breast Oncology, Brca1185stop Mutations, Brca1 Protein +18

Mammary-specific inactivation of E-cadherin and p53 impairs functional gland development and leads to pleomorphic invasive lobular carcinoma in mice

Patrick W.B. Derksen, Tanya M. Braumuller, Eline van der Burg et al. · Disease Models & Mechanisms · 2011 · 134 citations · Full text